FDA Approves Zongertinib for HER2-Mutated Lung Cancer in February 2026

The FDA's accelerated approval of zongertinib (Hernexeos) marks an important milestone in precision oncology for lung cancer patients. This targeted therapy specifically addresses a critical unmet need for patients whose tumors harbor HER2 (ERBB2) tyrosine kinase domain activating mutations.

Zongertinib received approval on February 26, 2026, for treating adults with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) with confirmed HER2 mutations. The drug targets the HER2 protein, which becomes overactive due to specific genetic mutations, driving cancer growth and progression.

This approval represents the latest advancement in genetically-targeted lung cancer treatments. The requirement for FDA-authorized testing ensures patients receive appropriate genetic screening before treatment initiation. This precision medicine approach maximizes therapeutic benefit while minimizing unnecessary exposure for patients without the target mutation.

The clinical significance extends beyond this single approval, as it follows other HER2-targeted therapies like sevabertinib, approved in late 2025. This growing arsenal of mutation-specific treatments reflects the evolving landscape of personalized cancer care, where genetic profiling increasingly guides treatment selection.

Accelerated approval indicates the FDA recognized significant clinical benefit based on preliminary data, though confirmatory trials will likely be required. For patients with HER2-mutated NSCLC, this approval provides a new therapeutic option in a disease setting with historically limited treatment choices.